Skip to main content

Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery

Neurological Sciences volume 38, pages 337–342 (2017)Cite this article

Abstract

Multiple sclerosis (MS) can impair cognitive functions even in the early stages. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery is very short and highly sensitive and can be used to evaluate cognitive status in the disease. Several clinical trials have shown beneficial effects of disease-modifying drugs (DMDs) on long-term cognitive measures which may even reduce cognitive deficits in MS patients. Relapsing remitting MS patients using DMDs were enrolled in the study and monitored for 12 months. BICAMS and the Expanded Disability Status Scale were applied to the study group. We evaluated and monitored 161 newly diagnosed cases of definite MS by the end of the trial. 110 patients (68.2%) were female. One hundred and two healthy subjects (female to male ratio 68:34) were enrolled into the study. MS patients were categorized into three DMT groups: IFNB1-a SC, IFNB1-b, and GA. Mean scores of all three cognitive tests (SDMT, BVMT-R, and CVLT-II) were significantly higher in the control group than in the MS patients. The number of cognitively impaired patients decreased from 31.7 to 21.7% on the basis of CVLT (p = 0.024), and 42 (26.1%) to 30 (18.6%) on the basis of BVMT-R at month 12. A significant difference was determined in terms of cognitive status between MS patients using both IFNB and GA and the healthy control group. Ours is the first study to compare IFNB and GA in terms of evaluating cognitive involvement and to use the BICAMS battery in monitoring treatment.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Atlas (2004) Country resources for neurological disorders. World Health Organization. http://apps.who.int/iris/bitstream/10665/43075/1/9241562838.pdf. Accessed 23 Nov 2016

  2. Rao SM (1995) Neuropsychology of multiple sclerosis. Curr Opin Neurol 8:216–220

    CAS  Article  PubMed  Google Scholar 

  3. Patti F (2009) Cognitive impairment in multiple sclerosis. Mult Scler 15(1):2–8

    CAS  Article  PubMed  Google Scholar 

  4. Lynch SG, Parmenter BA, Denney DR (2005) The association between cognitive impairment and physical disability in multiple sclerosis. Mult Scler 11:469–476

    Article  PubMed  Google Scholar 

  5. Rogers JM, Panegyres PK (2007) Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J Clin Neurosci 14:919–927

    Article  PubMed  Google Scholar 

  6. Achiron A, Polliack M, Rao SM, Barak Y, Lavie M et al (2005) Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves. J Neurol Neurosurg Psychiatry 76:744–749

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. Achiron A, Barak Y (2003) Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 74(4):443–446

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Schultheis MT, Garay E, DeLuca J (2001) The influence of cognitive impairment on driving performance in multiple sclerosis. Neurology 56(8):1089–1094

    CAS  Article  PubMed  Google Scholar 

  9. Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58:1602–1606

    CAS  Article  PubMed  Google Scholar 

  10. Bagert B, Camplair P, Bourdette D (2002) Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs 16:445–455

    Article  PubMed  Google Scholar 

  11. Rao SM (1990) A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. Medical College of Wisconsin, Milwaukee

    Google Scholar 

  12. Benedict RH, Fischer JS, Archibald CJ et al (2002) Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 16(3):381–397

    Article  PubMed  Google Scholar 

  13. Benedict RH, Cookfair D, Gavett R et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12(4):549–558

    Article  PubMed  Google Scholar 

  14. Langdon DW, Amato MP, Boringa J et al (2012) Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler. 18(6):891–898

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Benedict RH, Amato MP, Boringa J et al (2012) Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. BMC Neurol 12:55

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lim SY, Constantinescu CS (2010) Current and future disease-modifying therapies in multiple sclerosis. Int J Clin Pract 64(5):637–650

  17. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al (2000) Intramuscular interferon beta-1A therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343(13):898–904

    CAS  Article  PubMed  Google Scholar 

  18. Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A (2013) The effects of longterm interferon-beta-1b treatment on cognitive functioning inmultiple sclerosis: a 16-year longitudinal study. Mul Scler 19(13):1765–1772

  19. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF et al (2002) Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59(5):679–687

    CAS  Article  PubMed  Google Scholar 

  20. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L et al (2005) Diagnostic criteria formultiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 58(6):840–846

  21. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L et al (1991) Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41:692–696

    CAS  Article  PubMed  Google Scholar 

  22. Delis DC, Kramer JH, Kaplan E, Ober BA (2000) California Verbal Learning Test, second edition (CVLT-II). San Antonio, Psychological Corporation

  23. Benedict RHB (1997) The Brief visuospatial memory tEst Revised (BVMT-R). Lutz, Psychosocial Assessment Resources Inc

  24. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452

    CAS  Article  PubMed  Google Scholar 

  25. Patti F (2012) Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs 21(11):1679–1699

    CAS  Article  PubMed  Google Scholar 

  26. Ziemssen T, Calabrese P, Penner IK, Apfel R (2016) QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. J Neurol 263(4):784–791

    CAS  Article  PubMed  Google Scholar 

  27. Mori F, Kusayanagi H, Buttari F, Centini B, Monteleone F, Nicoletti CG, Bernardi G, Di Cantogno EV, Marciani MG, Centonze D (2012) Neurology Clinic, University of Tor Vergata, Rome, Italy, Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis. Funct Neurol 27(3):163–168

  28. Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O, for the COGIMUS Study Group (2013) Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One 8(8):e74111

    Article  Google Scholar 

  29. Penner I-K, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R (2012) Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler J 18(10):1466–1471

  30. Schwid SR, Goodman AD, Weinstein A, McDermott MP (2007) Johnson KP; Copaxone Study Group. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 255(1–2):57–63

    Article  PubMed  Google Scholar 

  31. Kappos L, Freedman MS, Polman CH et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8:987–997

    CAS  Article  PubMed  Google Scholar 

  32. Mikol DD, Barkhof F, Chang P et al (2008) REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7:903–914

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Neurology, Samsun Training and Research Hospital, Samsun, Turkey

    Bilge Piri Cinar

  2. Department of Neurology, Usak State Hosapital, Usak, Turkey

    Görkem Kösehasanoğulları

  3. Department of Neurology, Dokuz Eylul University, Izmir, Turkey

    Pinar Yigit & Serkan Ozakbas

Authors
  1. Bilge Piri Cinar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Görkem Kösehasanoğulları
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pinar Yigit
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Serkan Ozakbas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bilge Piri Cinar.

Ethics declarations

Funding

The authors received no support for the research, authorship, and/or publication of this article.

Conflict of interest

The author(s) have no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cinar, B.P., Kösehasanoğulları, G., Yigit, P. et al. Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery. Neurol Sci 38, 337–342 (2017). https://doi.org/10.1007/s10072-016-2775-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-016-2775-7

Keywords

  • Multiple sclerosis
  • Cognition
  • Disease-modifying drugs
  • BICAMS battery